Nantkwest, Inc. (NK)

Trade NK now with
7/31/2017 11:02:50 AM NantKwest Announces Durable Complete Responses In Phase I Trial Of ANK Cell Therapy
6/6/2017 8:04:46 AM NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials
3/20/2017 7:06:19 AM NantKwest: FDA Grant Of Orphan Drug Designation For ANK Natural Killer Cell Therapy In Merkel Cell Carcinoma
10/4/2016 10:01:55 AM Altor BioScience And NantKwest Announce Co-Development Deal To Advance Natural Killer Cell Combination Immunotherapies
5/23/2016 7:09:48 AM Tribune Publishing Gets $70.5 Mln Growth Capital Investment From Nant Capital
4/15/2016 9:37:04 PM NantKwest To Present Positive Preclinical Data On Next Generation GMP-Grade NK Cell Line For Combination Immunotherapy
3/14/2016 8:06:35 AM NantKwest Appoints Fatih Uckun As VP Of Research And Clinical Development
12/9/2015 8:08:32 AM NantKwest Announces Presentation Of Preclinical Data Of HER2.taNK
11/17/2015 6:05:13 AM NantKwest Says Names Angela Wilson As CFO
11/12/2015 8:04:21 AM NantKwest Announces $50 Mln Stock Repurchase Program
9/22/2015 11:02:56 AM NantKwest Appoints Andreas Niethammer Executive Medical Director; Dvorit Samid, As SVP Of Medical Affairs